New oral anticoagulants after acute coronary syndrome

被引:0
|
作者
Bennaghmouch, N. [1 ]
ten Berg, J. M. [1 ]
机构
[1] St Antonius Hosp Nieuwegein, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
关键词
antithrombins; anticoagulants; acute coronary syndrome; secondary prevention; factor Xa; thrombin; humans; ELEVATION MYOCARDIAL-INFARCTION; FACTOR XA INHIBITOR; LOWER CARDIOVASCULAR EVENTS; DUAL ANTIPLATELET THERAPY; DOUBLE-BLIND; ATRIAL-FIBRILLATION; ST-ELEVATION; SYNDROME-THROMBOLYSIS; SECONDARY PREVENTION; STANDARD THERAPY;
D O I
10.1016/j.beha.2013.07.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New oral anticoagulants (NOACs) have been developed that may further decrease the mortality and morbidity of ACS by complementing antiplatelet therapy. Optimal use of these agents can be achieved by maximum reduction in thrombotic events at the minimum bleeding risk when combining a long-term oral anticoagulant with anti-platelet therapy in patients with coronary heart disease. Although, based on the pharmacokinetics and -dynamics of NOACs, these agents could improve the current management of ACS patients, multiple trials consistently demonstrate a trend toward increased major and clinically relevant non major bleeding almost diminishing the benefits in reduction of ischemic events. Therefore, some critical issues need to be further evaluated in future trials. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 50 条
  • [31] Use of New Oral Anticoagulants in Antiphospholipid Syndrome
    Deepa Jayakody Arachchillage
    Hannah Cohen
    Current Rheumatology Reports, 2013, 15
  • [32] New Oral Anticoagulants for Acute Venous Thromboembolism
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1433): : 3 - 4
  • [33] Coronary Artery Ectasia in Acute Coronary Syndrome: The Role of Non-vitamin K Antagonist Oral Anticoagulants in Management
    Izraiq, Mahmoud
    Alshoubaki, Nail
    Abu-Dhaim, Omran A.
    Aqel, Raed
    INTERVENTIONAL CARDIOLOGY-REVIEWS RESEARCH RESOURCES, 2024, 19
  • [34] New Anticoagulants in the Treatment of Patients With Recent Acute Coronary Syndrome. Place of Rivaroxaban
    Hirmanov, V. N.
    KARDIOLOGIYA, 2015, 55 (06) : 98 - 104
  • [35] Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome
    Sharma, Abhishek
    Garg, Akash
    Borer, Jeffrey S.
    Krishnamoorthy, Parasuram
    Garg, Jalaj
    Lavie, Carl J.
    Arbab-Zadeh, Armin
    Mukherjee, Debabrata
    Ahmad, Hasan
    Lichstein, Edgar
    CARDIOLOGY, 2014, 129 (04) : 224 - 232
  • [36] Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review
    Khalil, Peter
    Kabbach, Ghazal
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (01)
  • [37] Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review
    Peter Khalil
    Ghazal Kabbach
    Current Cardiology Reports, 2019, 21
  • [38] New oral anticoagulants Regional anaesthesia and new oral anticoagulants
    Standl, Thomas
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2014, 49 (03): : 192 - 195
  • [39] The Role of the Novel Oral Anticoagulants in the Secondary Prevention of Acute Coronary Syndromes
    Sharma, Rajat
    Bainey, Kevin R.
    CARDIOLOGY IN REVIEW, 2015, 23 (02) : 99 - 102
  • [40] No Place for Novel Oral Anticoagulants in Current Treatment of Acute Coronary Syndromes
    Hernandez, Adrian V.
    ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (20) : 1546 - 1547